▷ Biocytogen / Eucure Biopharma announce completion of first patient dosing for …


10.12.2021 – 19:02

Biocytogen

Beijing (ots/PRNewswire)

Eucure Biopharma, a wholly owned subsidiary of Biocytogen, announced the first patient dose for a Phase I clinical trial of YH004 (monoclonal antibody to 4-1BB, mAb) (# YH004002) in Australia.

The study is an open, multicenter, classic dose escalation study of phase I. YH004Monotherapy or YH004 in combination with an anti-PD-1-MAK. Subjects are patients with advanced solid tumors or relapsed / refractory non-Hodgkin lymphoma (R / R NHL). The aim of the study is to investigate the safety, tolerability and efficacy of YH004 alone or in combination with anti-PD-1 MAK in patients with advanced solid tumors or R / R-NHL. The pharmacokinetics and immunogenicity of YH004 also be investigated.

Dr. Yuelei Shen, chairman and CEO of Biocytogen and Eucure Biopharma, said Eucure Biopharma plans to move ahead with clinical trials of YH004 so that patients around the world can have access to the therapy as soon as possible.

Over YH004

YH004 is a humanized, agonistic monoclonal antibody (mAb) of the IgG1 type, which targets 4-1BB with high affinity and specificity. YH004 can enhance the immune response against tumors through several mechanisms. Antibody-mediated activation of 4-1BB can increase the co-activation of T cells and the cytotoxicity of NK cells, promote the maturation of antigen presenting cells (APCs), and inhibit regulatory T cells (Tregs). Both in vitro and in vivo data indicate that YH004 alone or in combination with an anti-PD-1 antibody has significant anti-tumor activity with good safety and tolerability.

About Eucure Biopharma

Eucure Biopharma is responsible for the clinical development of Biocytogen’s R&D pipelines. Eucure Biopharma has a strong clinical development team with extensive experience developing innovative drugs for oncology and other indications to meet the clinical needs of patients around the world. The company has created a pipeline of more than 10 goals. Currently, four products have received clinical trial approvals in the US and China, including two products that have received Phase II clinical approval from both FDA and NMPA, two products entering clinical phase in China I have occurred, and four products that are based in Australia in phase I clinical trials.

Over Biocytogen

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a global biotech company that drives the research and development of new drugs with innovative technologies. use of RenMabTM and RenLiteTM-Mice for the production of fully human antibodies, Biocytogen has integrated its monoclonal and bispecific antibody development platforms, in vivo drug efficacy screening platforms, and strong clinical development capabilities to streamline the entire drug development process . Biocytogen is running a large-scale antibody drug development project in collaboration with global partners for more than 1000 drug targets, known as the RenMiceTM HiTS platform. Biocytogen is headquartered in Beijing and has offices in Haimen Jiangsu, Shanghai and Boston, USA.

[email protected]

Media contact:

Jenna Frame
[email protected]https://mma.prnewswire.com/media/1358305/Biocytogen_Logo.jpg

Original content by: Biocytogen, transmitted by news aktuell


www.presseportal.de

Leave a Reply

Your email address will not be published.